세계 세포 분석 시장 규모는 2024년 222억 달러에 달했습니다. IMARC Group은 이 시장이 2033년까지 412억 달러에 달하고, 2025-2033년까지 7.1%의 연평균 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 개인 맞춤형 의료로의 전환, 전 세계 암 환자 증가, 세포 분석에서 인공지능과 머신러닝의 통합 확대 등이 시장 성장의 촉매제 역할을 하고 있습니다.
암 환자 수 증가
세계적으로 암 환자 수가 증가하고 있는 것이 시장 성장의 주요 원동력이 되고 있습니다. 암 연구의 세포 분석 도구와 기술을 통해 종양 세포의 유전자 변이, 단백질 발현 프로파일, 종양 미세환경 내 세포 간 상호작용 등 종양 세포의 정확한 특성 분석이 가능합니다. 암 환자 증가는 세포 분석 시장 점유율의 촉매제 역할을 하고 있습니다. 예를 들어, 미국암협회(American Cancer Society)의 2022년 최신 정보에 따르면, 미국에서는 2022년 약 191만 8,030명의 신규 암 환자가 발생할 것으로 추정됩니다. 또한, 폐암과 유방암은 가장 흔한 두 가지 암입니다. 캐나다암협회(CCS)에 따르면, 2020년에는 약 2만 9,800명의 캐나다인이 폐암 진단을 받았으며, 이는 전체 신규 암 환자의 13%를 차지합니다. 또한 약 2만 1,200명의 캐나다인이 폐암으로 사망할 것으로 예상되며, 이는 2020년 전체 암 사망자의 25%를 차지할 것으로 예측됩니다. 이는 보다 효과적이고 진보된 암 치료에 대한 요구가 높아지고 있음을 보여줍니다. 이처럼 효과적이고 지속적인 암 치료에 대한 수요 증가는 시장 전체에 유리한 성장 기회를 제공할 것으로 예측됩니다.
신규 분자 개발 증가
다양한 감염병의 유행은 새로운 분자 및 백신 개발을 촉진하고, 세포 분석 시장의 수익을 증대시키고 있습니다. 세포 분석 도구는 연구자들이 잠재적 약물 후보물질의 유효성, 안전성, 작용기전을 평가할 수 있도록 함으로써 신약개발에 중요한 역할을 하고 있습니다. 또한, 다양한 제약사 및 생명공학 기업들은 신약 및 개량신약을 도입하기 위해 세포 분석 기술 및 도구에 대한 의존도를 높이고 있습니다. 예를 들어, 미국 의회 예산국이 발표한 자료에 따르면, 2021년 제약업계는 2020년 전 세계 연구개발에 약 2,000억 달러를 지출한 반면, 2019년에는 8,300만 달러를 지출한 것으로 확인되었습니다. 마찬가지로 Danaher Corporation은 2020년에 13억 4,800만 달러를 연구개발에 투자한 반면 2021년에는 17억 4,200만 달러를 투자할 예정입니다. 또한, Bio-Rad Laboratories Inc.는 2020년 8억 3,000만 달러에 비해 2021년에는 8억 7,960만 달러를 투자할 예정입니다. 이처럼 기업의 R&D 투자 증가는 혁신적인 세포 분석 기술을 채택하는 기업의 능력을 더욱 향상시켜 세포 분석 시장의 성장을 가속하고 있습니다.
전략적 제휴 및 인수합병 증가
세포 분석의 새로운 방법, 도구, 기술을 개발하기 위해 다양한 주요 기업들이 파트너십과 제휴를 맺고 있습니다. 예를 들어, 수상 경력에 빛나는 CellDrop Automated Cell Counter 제조업체인 DeNovix Inc.는 2022년 8월, 분리된 핵과 손상되지 않은 세포를 파편으로부터 구별할 수 있는 두 가지 핵 계수 전용 앱을 개발했습니다. CellDrop 시리즈는 이미지 기반 자동 셀 카운터 라인입니다. 이 시스템에는 라이브 미리보기 및 결과의 즉각적인 검토를 위한 고화질 7인치 터치스크린이 포함되어 있습니다. 또한, 2022년 11월에는 유세포분석기에서 얻은 데이터를 이용하여 다양한 세포 집단에서 암세포, 줄기세포 등 희귀세포를 신속하게 식별할 수 있는 유세포분석 데이터 분석 클라우드 솔루션 'SFA-Life Sciences Cloud Platform'의 제공을 시작했습니다. 이와 더불어, Thermo Fisher Scientific은 2022년 3월에 세포 치료 개발을 가능하게 하는 새로운 대용량 전기포레이션 시스템을 발표했습니다. 이러한 기술 혁신은 향후 몇 년 동안 세포 분석 시장 수요를 강화할 것으로 예측됩니다.
The global cell analysis market size reached USD 22.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 41.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033. The shift towards personalized medicine, increasing cases of cancer across the globe, and growing integration of artificial intelligence and machine learning in cell analysis are some of the key factors, catalyzing the growth of the market.
Growing Burden of Cancer
The rising number of cancer cases across the world is primarily driving the market growth. Cell analysis tools and techniques in cancer research enable precise characterization of tumor cells, including their genetic mutations, protein expression profiles, and cellular interactions within the tumor microenvironment. The growing number of cancer patients is catalyzing the cell analysis market share. For instance, as per an American Cancer Society 2022 update, around 1,918,030 new cancer cases were estimated in the U.S. in 2022. Furthermore, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer cell analysis. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.
Increasing Development of Novel Molecules
The rising prevalence of various infectious diseases is prompting the development of novel molecules and vaccines, which in turn is augmenting the cell analysis market revenue. Cell analysis tools play a crucial role in drug discovery and development by enabling researchers to assess the efficacy, safety, and mechanism of action of potential drug candidates. Furthermore, various pharmaceutical and biotech firms are increasingly relying on cell analysis techniques and tools to introduce new and improved drugs. For instance, according to the data published by the Congressional Budget Office, in 2021, it was observed that pharmaceutical industries spent nearly USD 200 Billion on research and development in 2020 globally, compared to USD 83 Million in 2019. Similarly, Danaher Corporation invested USD 1,742 Million in its research and development in 2021, as compared to USD 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc., invested USD 879.6 Million in 2021 as compared to USD 800.3 Million in 2020. Thus, the rising investment in research and development by the companies further increases the capabilities of the company to adopt innovative cell analysis techniques, thereby propelling the cell analysis market growth.
Rising Number of Strategic Collaborations and Acquisitions
Various key market players are forming partnerships and collaborations to develop new and improved cell analysis methods, tools, and techniques. For instance, in August 2022, DeNovix Inc., the manufacturer of the award-winning CellDrop Automated Cell Counter, developed two dedicated nuclei counting apps capable of differentiating isolated nuclei and intact cells from debris. The CellDrop Series is a line of image-based, automated cell counters. Systems include a high-definition 7-inch touchscreen for live preview and instant review of results. Similarly, in November 2022, Sony Corporation launched the SFA - Life Sciences Cloud Platform, a flow cytometry data analysis cloud solution that can quickly identify rare cells, such as cancer cells and stem cells, from a wide variety of cell populations, using data obtained from flow cytometers. In addition to this, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that is intended to enable the development of cell therapies. Such innovations are expected to bolster the cell analysis market demand in the coming years.
Flow cytometry products exhibit a clear dominance in the market
The cell analysis market report has provided a detailed breakup and analysis of the market based on the product. This includes flow cytometry products, qPCR Products, cell microarrays, microscopes, spectrophotometers, cell counters, HCS systems, and others. According to the report, flow cytometry products exhibit a clear dominance in the market.
Flow cytometry products are pivotal in the cell analysis market, offering precise quantification and characterization of cells based on their physical and chemical properties. Key components include flow cytometers, which analyze cells in fluid suspension using lasers to detect fluorescently labeled cells. Reagents such as fluorescent dyes and antibodies enable specific labeling for biomarker detection, while software facilitates data analysis and visualization. These products are essential in research, clinical diagnostics, and drug discovery, providing insights into cell function, differentiation, and disease mechanisms. Ongoing advancements in technology are enhancing sensitivity, multiplexing capabilities, and automation, expanding the utility of flow cytometry in diverse biomedical applications.
Cell identification analysis type holds the majority of the total market share
The cell analysis market research report has provided a detailed breakup and analysis of the market based on the analysis type. This includes cell identification, cell viability, cell signaling pathways/signal transduction, cell proliferation, cell counting and quality control, cell interaction, target identification and validation, single-cell analysis, and others. According to the report, cell identification analysis type holds the majority of the total market share.
Cell identification in cell analysis involves various techniques to distinguish and classify cells based on their morphological, molecular, or functional characteristics. Methods include microscopy for visual inspection, flow cytometry for quantitative analysis of cell surface markers, and molecular techniques like PCR for genetic profiling. Immunohistochemistry and immunofluorescence enable detection of specific proteins within tissues or cell samples. Advances in single-cell analysis technologies allow for high-resolution characterization of individual cells within heterogeneous populations. Accurate cell identification is crucial in understanding disease mechanisms, assessing treatment responses, and advancing personalized medicine by tailoring therapies based on individual cell profiles.
Molecular approaches represent the largest market share
Molecular approaches in cell analysis focus on studying cellular components at the molecular level to understand biological processes and diseases. Techniques include PCR (Polymerase Chain Reaction) for amplifying and detecting DNA or RNA sequences, Western blotting for protein detection and quantification, and next-generation sequencing (NGS) for comprehensive genomic analysis. These methods enable researchers to investigate gene expression, mutations, protein interactions, and epigenetic modifications within cells. Molecular approaches are vital in biomarker discovery, drug development, and personalized medicine, offering insights into cellular function and disease mechanisms with high sensitivity and specificity. Continued advancements enhance their utility in diverse biomedical research applications.
Pharmaceutical and biotechnology companies and CROs currently account for the majority of the total market share
Pharmaceutical and biotechnology companies develop and commercialize drugs and therapies for medical use. They conduct extensive research and clinical trials to discover new compounds, validate their efficacy and safety, and obtain regulatory approvals. Contract Research Organizations (CROs) support these efforts by providing specialized, such as clinical trial management, data analysis, and regulatory compliance. CROs enable companies to outsource non-core activities, accelerate timelines, and manage costs effectively. Furthermore, the increasing rate of new drug development is also contributing to the segment's growth. For instance, between 2010 and 2019, around 38 new drugs were approved each year, on an average. That is about a 60% increase compared with the previous decade. Drug approvals reached a new peak in 2018, surpassing the record number of approvals of the late 1990s. The cell analysis market statistics by IMARC indicate that together, pharmaceutical/biotech firms and CROs are playing crucial roles in advancing healthcare innovation, bringing new treatments to market, and improving patient outcomes through rigorous scientific research and development.
North America currently dominates the global market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.
The growth of the region can be attributed to the increase in incidences of cancer and rising corporate and government funding in cell-based research. For instance, according to the Canadian Cancer Statistics 2022 Special Report, the number of people living with and after cancer in Canada continued to grow to over 1.5 million people. Additionally, according to another report, 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. Besides this, the presence of major companies, the growing number of product launches, and the strong R&D in biotechnology are further positively impacting the cell analysis market outlook. For instance, in September 2022, Becton, Dickinson, and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.